About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

In Severe COVID-19 Patients, Arthritis Drug Shows No Response

by Pooja Shete on January 24, 2021 at 1:00 AM
Font : A-A+

In Severe COVID-19 Patients, Arthritis Drug Shows No Response

In severe or critical COVID-19 patients in hospital, addition of the arthritis drug tocilizumab to standard care is not better than the standard care alone in improving the clinical outcomes after 15 days.

The findings of this trial are published in the journal The BMJ

Advertisement


The trial was stopped early as there was an increased number of deaths in patients receiving tocilizumab.

The result of this study contradicts the previous observational studies that suggested possible benefits of tocilizumab. Observational studies are limited as they have a high risk of other unknown factors which can influence the study.
Advertisement

Tocilizumab acts by blocking interleukin 6, a specific part of the immune system that can go into overdrive in some COVID-19 patients. This can help reduce the body's inflammatory response to the virus and avoid some of the more dire consequences of the disease. However, its effects are not well defined.

The researchers conducted a randomized controlled trial and compared tocilizumab plus standard care with standard care alone in patients admitted to hospital with severe or critical COVID-19. For the study, 129 relatively young adults (average age 57 years) with confirmed COVID-19 were selected.

The patients received supplemental oxygen or mechanical ventilation and also had abnormal levels of at least two chemicals linked to inflammation in their blood. Patients were divided into two groups, first group consisted of 65 patients who received tocilizumab plus standard care and 64 received standard care alone.

The patients were monitored for 15 days and other important factors like underlying conditions and the use of other medication, were taken into account. At the end of day 15, 28 percent patients (18 patients) in the tocilizumab group and 20 percent (13 patients) of patients received mechanical ventilation or died.

At the end of day 15, 11 patients died in the tocilizumab group compared to 2 patients in the standard care group. The trial was stopped early due to the safety concerns. In both groups, deaths occurred due respiratory failure or multiple organ dysfunction.

The researchers said, "Tocilizumab plus standard care was not superior to standard care alone in improving clinical status at 15 days and might increase mortality. The results raise questions about an anti-inflammatory approach in the treatment of covid-19 beyond corticosteroids."

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Can Exercise Counts Boost Your Life Counts? 
Prevent Hacking of Medical Devices: FDA Sounds Alarm
Black Water: Benefits and Uses
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Osteoarthritis Oligoarthritis Spondylolisthesis Signature Drug Toxicity Knee Replacement Reactive Arthritis Drugs Banned in India Arthritis Septic Arthritis 

Most Popular on Medindia

Selfie Addiction Calculator Pregnancy Confirmation Calculator Post-Nasal Drip Sanatogen Blood Donation - Recipients Iron Intake Calculator Noscaphene (Noscapine) Turmeric Powder - Health Benefits, Uses & Side Effects A-Z Drug Brands in India Loram (2 mg) (Lorazepam)

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use